Alpha 2.0
Login Register
» Authors » L Sreenivasa Murthy

L Sreenivasa Murthy

Explore the profile of L Sreenivasa Murthy including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 11
Followers 0
Related Specialties
General Medicine
Endocrinology
Top 10 Co-Authors
Rakesh Sahay
Prakash Kurmi
Sadhna J Joglekar
K D Modi
Gaurav Chaudhary
Girish Mathur
Shital R Karnawat
Sujoy Ghosh
T P Ajish
Preeti Nikam
Published In
J Assoc Physicians India
Adv Ther
Diabetes Obes Metab
Metabol Open
Affiliations
Soon will be listed here.
Recent Articles
1.
Fixed dose combination of dapagliflozin, glimepiride and extended-release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase III, open label, randomized clinical study in India
Sahay R, Gangwani D, Singh M, Gupta S, Kale N, Srivastava M, et al.
Diabetes Obes Metab . 2025 Feb; 27(4):2193-2205. PMID: 39950245
Aim: To evaluate the efficacy and safety of a triple fixed-dose combination (FDC) therapy of dapagliflozin + glimepiride + metformin hydrochloride extended-release (DAPA + GLIM + MET ER) tablets in...
2.
Efficacy of Dapagliflozin + Sitagliptin + Metformin Versus Sitagliptin + Metformin in T2DM Inadequately Controlled on Metformin Monotherapy: A Multicentric Randomized Trial
Singh A, Das A, Murthy L, Ghosal S, Sahay R, Harikumar K, et al.
Adv Ther . 2024 Dec; 42(2):801-812. PMID: 39636567
Introduction: A slower adoption rate of fixed dose combinations (FDC) in diabetes management is partly due to insufficient data. This study evaluates the safety and efficacy of an FDC of...
3.
Management of Hypertension in Patients with Type 2 Diabetes Mellitus: Indian Guideline 2024 by Association of Physicians of India and Indian College of Physicians
Wander G, Panda J, Pal J, Mathur G, Sahay R, Tiwaskar M, et al.
J Assoc Physicians India . 2024 Aug; 72(8):e1-e25. PMID: 39163066
In India and the Southeast Asian population, hypertension and type 2 diabetes mellitus (T2DM) are the leading lifestyle-related diseases, responsible for a majority burden of morbidity and mortality. Multiple population-spanning...
4.
Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations
Sahay R, Giri R, Shembalkar J, Gupta S, Mohan B, Kurmi P, et al.
Adv Ther . 2023 May; 40(7):3227-3246. PMID: 37258803
Introduction: This study compared efficacy and safety of triple drug fixed-dose combination (FDC) of dapagliflozin (DAPA) + sitagliptin (SITA) + metformin (MET) extended release (ER) with SITA + MET sustained...
5.
One-year safety and effectiveness of insulin degludec in patients with diabetes mellitus in routine clinical practice in India-TRUST (Tresiba real-world use study)
Kesavadev J, Murthy L, Chaudhury T, Yalamanchi S, Giri J, Gupta S, et al.
Metabol Open . 2022 May; 14:100184. PMID: 35496980
Objective: This post-authorization safety study (PASS) was conducted to evaluate the long-term safety and effectiveness of insulin degludec in patients with diabetes mellitus (DM) requiring insulin therapy in routine clinical...
6.
Blood-pressure Lowering Efficacy and Safety of Perindopril / Indapamide / Amlodipine Single-pill Combination in Hypertensive Patients: Phase III Trial in India
Thacker H, Konda Reddy K, Murthy L, Sawhney J, Chaudhary G, Shah S, et al.
J Assoc Physicians India . 2020 Sep; 68(10):39-43. PMID: 32978924
Background: Hypertension is the biggest contributor to global burden of disease and mortality. Increasing compliance with antihypertensive treatment and achieving a wide BP control in the population represents a major...